​

BeOne Medicines (ONC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ONC Stock Forecast

BeOne Medicines (ONC) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $406.60, with a high of $420.00 and a low of $394.00. This represents a 13.24% increase from the last price of $359.05.

ONC Stock Rating

BeOne Medicines stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

ONC Price Target Upside V Benchmarks

TypeNameUpside
StockBeOne Medicines13.24%
SectorHealthcare Stocks 15.45%

Price Target Trends

1M3M12M
# Anlaysts149
Avg Price Target$394.00$403.25$378.67
Last Closing Price$359.05$359.05$359.05
Upside/Downside9.73%12.31%5.46%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 26719-1-27
Jan, 2671811-27
Dec, 2571811-27
Nov, 2581711-27
Oct, 2581711-27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 04, 2026Barclays$394.00$346.3813.75%9.73%
Jan 12, 2026Bernstein$414.00$337.8922.53%15.30%
Jan 08, 2026Morgan Stanley$405.00$333.8721.30%12.80%
Nov 24, 2025Truist Financial$400.00$347.7215.04%11.41%
Nov 17, 2025Jefferies$420.00$376.6311.52%16.98%
Oct 20, 2025Sean LaamanMorgan Stanley$383.00$319.1919.99%6.67%
Sep 18, 2025Barclays$385.00$337.4314.10%7.23%
Mar 13, 2025Bernstein$259.00$254.571.74%-27.87%
Feb 28, 2025JMP Securities$348.00$271.8028.04%-3.08%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 04, 2026BarclaysOverweightOverweighthold
Jan 12, 2026BernsteinOutperformupgrade
Jan 08, 2026Morgan StanleyOverweightOverweighthold
Dec 17, 2025RBC CapitalOutperformOutperformhold
Nov 17, 2025JefferiesBuyBuyhold
Oct 20, 2025Morgan StanleyOverweightOverweighthold
Sep 18, 2025BarclaysOverweightinitialise
Apr 07, 2025RBC CapitalOutperforminitialise
Feb 28, 2025MacquarieOutperformOutperformhold
Feb 28, 2025GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$-6.12--
Avg Forecast$-5.83$-0.02$5.53
High Forecast$-5.20$2.11$8.75
Low Forecast$-6.62$-3.52$0.75
Surprise %4.97%--

Revenue Forecast

$4B $4B $5B $6B $7B $8B Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$3.81B--
Avg Forecast$3.77B$4.84B$5.98B
High Forecast$3.78B$4.96B$7.00B
Low Forecast$3.75B$4.71B$5.02B
Surprise %1.07%--

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$-644.79M--
Avg Forecast$-613.83M$-2.11M$582.26M
High Forecast$-547.50M$222.16M$921.72M
Low Forecast$-697.01M$-370.61M$78.97M
Surprise %5.04%--

ONC Forecast FAQ

Is BeOne Medicines stock a buy?

BeOne Medicines stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BeOne Medicines is a favorable investment for most analysts.

What is BeOne Medicines's price target?

BeOne Medicines's price target, set by 11 Wall Street analysts, averages $406.6 over the next 12 months. The price target range spans from $394 at the low end to $420 at the high end, suggesting a potential 13.24% change from the previous closing price of $359.05.

How does BeOne Medicines stock forecast compare to its benchmarks?

BeOne Medicines's stock forecast shows a 13.24% upside, underperforming the average forecast for the healthcare stocks sector (15.45%).

What is the breakdown of analyst ratings for BeOne Medicines over the past three months?

  • February 2026: 25.93% Strong Buy, 70.37% Buy, 0% Hold, 3.70% Sell, 0% Strong Sell.
  • January 2026: 25.93% Strong Buy, 66.67% Buy, 3.70% Hold, 3.70% Sell, 0% Strong Sell.
  • December 2025: 25.93% Strong Buy, 66.67% Buy, 3.70% Hold, 3.70% Sell, 0% Strong Sell.

What is BeOne Medicines’s EPS forecast?

BeOne Medicines's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.02, marking a -99.67% decrease from the reported $-6.12 in 2024. Estimates for the following years are.

What is BeOne Medicines’s revenue forecast?

BeOne Medicines's average annual revenue forecast for its fiscal year ending in December 2025 is $4.84B, reflecting a 27.03% increase from the reported $3.81B in 2024. The forecast for.

What is BeOne Medicines’s net income forecast?

BeOne Medicines's net income forecast for the fiscal year ending in December 2025 stands at $-2.106M, representing a -99.67% decrease from the reported $-645M in 2024. Projections indicate .